The biggest bet AI medicine has ever placed landed the same week a trial showed how stubborn the last mile really is.
This was a week of enormous checks and pointed questions. Isomorphic Labs raised $2.1 billion to design drugs with AI — among the largest rounds the field has ever seen — while a fresh randomized trial and a run of journal editorials pressed a harder one: does any of this change outcomes? For builders, the distance between a model that scores well and a tool that changes what a clinician actually does has never been more visible, or better funded.
Watch & Listen First
NEJM AI Grand Rounds — "The OpenEvidence Episode: Dr. Travis Zack on the Future of Clinical Evidence" · May 20 · NEJM AI Grand Rounds
→ OpenEvidence's chief medical officer on why clinical decision support has to surface reasoning and cited literature — not just an answer a physician can't audit.
How AI Aims to Fix Healthcare Access · May 14 · Bloomberg
→ Rezilient CEO Danish Nagda makes the operational case for AI-staffed "cloud clinics" cutting primary-care wait times and switching costs.
Key Takeaways
- The money is years ahead of the evidence. Isomorphic's $2.1B lands before a single molecule from its engine reaches a patient.
- Pathology is the next regulatory frontier. Valar's bladder-cancer test is the first AI digital-pathology prognostic to win FDA Breakthrough status.
- Behavioral health is going foundation-model. ARPA-H is funding a bet that passive phone signals can flag a mental-health crisis before it happens.
- A null trial is useful data. PRIMA-AI shows an accurate risk score does not automatically improve the decision built on top of it.
- The "show us the outcomes" era has started. Journals, regulators and payers are converging on real-world endpoints over AUROC.
The Big Story
Isomorphic Labs raises $2.1B to scale its AI drug-design engine · May 13 · Isomorphic Labs
→ The DeepMind spinout's Series B — led by Thrive Capital with Alphabet, GV, Temasek, MGX, CapitalG and the UK Sovereign AI Fund — is among the largest ever raised in AI drug discovery, and it funds IsoDDE, the engine that pairs with AlphaFold 3 to predict how molecules behave in the body. The clinically important caveat: Isomorphic has no candidate in humans and plans its first trial only by end of 2026, so this is a bet on a platform, not a readout. In an industry where roughly 90% of drugs entering clinical testing still fail, the capital is wagering that the discovery bottleneck is being solved faster than the development one — while the expensive part, proving a drug works in patients, has not moved.
Also This Week
Anthropic and the Gates Foundation launch a four-year, $200M health and development partnership · May 14 · Anthropic
→ Grant funding, API credits and engineering support aimed first at polio, HPV and pre-eclampsia — putting frontier LLMs into systematic reviews, candidate screening and disease surveillance for conditions pharma chronically underinvests in.
Valar Labs' Vesta bladder-cancer test earns FDA Breakthrough Device Designation · May 15 · Urology Times
→ The first AI digital-pathology prognostic in bladder cancer to win Breakthrough status reads routine H&E slides for risk stratification — a signal the FDA's appetite for foundation-model pathology now extends beyond detection into prognosis.
Ksana Health wins an ARPA-H contract to build a behavioral-health foundation model · May 14 · PR Newswire
→ The "Large Health Behavior Model," funded up to $17.9M, will train on passive smartphone signals — sleep, mobility, communication patterns — linked to EHR data to predict mental-health and substance-use crises before they escalate.
An AI avatar 'doctor' improved patient comprehension before radiation-oncology consults · May 17 · Bioengineer
→ Presented at ESTRO 2026, a pre-visit AI avatar beat standard explainer videos on comprehension and anxiety — a low-risk, non-diagnostic use case health systems can deploy now.
From the Lab
PRIMA-AI: a randomized trial of EHR-integrated AI risk estimates in kidney transplantation · npj Digital Medicine
→ In a German randomized trial of roughly 76 transplant recipients, surfacing passive AI-generated risk scores to clinicians and patients did not improve shared decision-making — a reminder that an accurate model delivered without workflow redesign changes little. Negative trials like this are exactly the evidence the field has been short on.
A 50-country survey of physician AI adoption · npj Digital Medicine
→ Across 1,049 physicians, 80% believed AI improves their practice but only 28% used it clinically; formal training was the strongest predictor of real use — the adoption gap is as much an education problem as a technology one.
Worth Reading
- Show us the evidence for the value of medical AI — Nature Medicine argues adoption is outpacing proof, and lays out what real clinical evidence should actually look like.
- Demis Hassabis on Google's AI and the 'foothills of the singularity' — Context on the worldview underwriting Isomorphic's raise — and how Hassabis frames AI's path to "curing disease."
- Clinical LLMs live or die on context engineering — A practical BMJ Digital Health piece on why selecting and structuring the right patient context beats swapping the base model.
The money is underwriting 2030; the evidence is still arguing about whether the tool helped on Tuesday.